undamentalytics Newsletter
Sign in

Medicus Pharma Ltd. (MDCX) stock

Add to watchlist

Add holding +

NASDAQ: MDCX Nasdaq Biotechnology

Medicus Pharma Ltd. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds14 adding, 10 cuttingOf 1 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 31% in the quarter to 2026-06-30.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Medicus Pharma Ltd.'s latest figures clears our strength thresholds.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 135% and a beta of 2.3 against the S&P 500.
  • Missing expectations. Earnings per share fell short of the consensus estimate in 4 of the last four quarters.

Latest results

Earnings per share
-$10.50 against an average estimate of -$8.00: missed by 31.2%

Medicus Pharma's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+2.7%
  • 1 week-23.1%
  • 1 month-76.0%
  • This year-97.5%
  • 1 year-98.4%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Governance
  3. Announcement
  4. Agreement ended
  5. Share issue
  6. Agreement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Medicus Pharma Ltd. valuation models and calculator

No model value for Medicus Pharma Ltd. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Medicus Pharma Ltd. as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no twelve-month earnings or share count in the filings yet
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: no twelve-month earnings or share count in the filings yet
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: no twelve-month earnings or share count in the filings yet
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no twelve-month earnings or share count in the filings yet
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Medicus Pharma Ltd. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$27.00 +73% — 0%
Next −$13.61 +59% — 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −55.4% on 90 days ago. In the last 30 days, 0 analysts raised Medicus Pharma Ltd.'s forecast and 0 cut it.

Consensus EPS forecast Medicus Pharma Ltd., last 90 days
−$80.00 −$60.00 −$40.00 −$20.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$60.50 Current fiscal year, 60 days ago: −$60.50 Current fiscal year, 30 days ago: −$31.50 Current fiscal year, 7 days ago: −$31.50 Current fiscal year, Now: −$27.00 −$27.00 Next fiscal year, 90 days ago: −$19.50 Next fiscal year, 60 days ago: −$18.83 Next fiscal year, 30 days ago: −$14.67 Next fiscal year, 7 days ago: −$14.67 Next fiscal year, Now: −$13.61 −$13.61

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$60.50−$19.50
60 days ago −$60.50−$18.83
30 days ago −$31.50−$14.67
7 days ago −$31.50−$14.67
Now −$27.00−$13.61

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$8.00 −$10.50 −31.2%
Mar 2026 −$11.00 −$15.09 −37.2%
Dec 2025 −$14.50 −$22.21 −53.2%
Sept 2025 −$19.00 −$54.66 −187.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

4 analysts, Oct 2026
Buy4100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026134
  2. Sep 2026134
  3. Aug 2026134
  4. Jul 2026134

Counts of recommendations published by analysts covering Medicus Pharma Ltd., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
3.2%
of tradable shares
Days to cover
0.45
at average volume
Short interest, 1 month
−56%
to October 15, 2026
Held by institutions
3%
of shares
Held by insiders
15.4%
of shares
Employees
16
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20252026 to date
Return
MDCX−37%−98%
Industry peers (median)−5%−26%
S&P 500+18%+11%
Months that ended higher
MDCX50%36%
S&P 50075%46%
Largest fall from a high during the year
MDCX−81%−98%
S&P 500−19%−9%

Worst fall since November 14, 2024: 100% from May 19, 2025 to October 30, 2026. Getting back needed a 20592% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.88 – $121.00
From 52-week high
−98.4%
vs 50-day average
−72.6%
vs 200-day average
−91.4%
Volatility (1 year)
135%
Beta vs S&P 500
2.34

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$1.2M
Institutions reporting
21
Shares held vs prior quarter
▲ 298.5%
Positions opened / closed
8 / 7

Top buyers and sellers, Q2 2026: 14 institutions bought and 10 sold ; the biggest buyer was Jane Street Group, LLC (+334K shares) and the biggest seller Private Advisor Group, LLC (−240K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Interchange Capital Partners, LLC $718,376 1.6M 60.9% —
Jane Street Group, LLC $148,918 334K 12.6% New
Xtx Topco Ltd $108,612 243K 9.2% New
Sterling Investment Advisors, Ltd. $44,630 100K 3.8% New
Commonwealth Equity Services, LLC $23,490 53K 2.0% ▲ 9.3%
May Hill Capital, LLC $22,593 51K 1.9% 0.0%
Susquehanna International Group, LLP $14,041 31K 1.2% New
Stifel Financial Corp $13,389 30K 1.1% New
Jpmorgan Chase & Co $12,498 26K 1.1% New
Wilmington Savings Fund Society, Fsb $11,435 26K 1.0% ▼ 50.0%
Citadel Advisors LLC $11,203 25K 0.9% ▲ 40.8%
Smithfield Trust Co $11,000 25K 0.9% ▲ 114.4%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Medicus Pharma Ltd.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Medicus Pharma Ltd. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Medicus Pharma Ltd. in brief

What does Medicus Pharma Ltd. do?
Medicus Pharma Ltd. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Medicus Pharma Ltd.'s stock ticker?
Medicus Pharma Ltd. trades under the ticker MDCX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Medicus Pharma Ltd.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Interchange Capital Partners, LLC, Jane Street Group, LLC and Xtx Topco Ltd. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.